CRAMP1L inhibitors represent a distinct class of small molecules that target the CRAMP1L (Cathelicidin-related antimicrobial peptide 1-like) protein, which plays a significant role in various biological processes, including immune response and inflammation. These inhibitors are primarily characterized by their ability to modulate the activity of CRAMP1L, often through competitive binding or allosteric modulation. By interfering with the protein's function, CRAMP1L inhibitors can influence signaling pathways that are crucial for cellular communication and response to external stimuli. The design of these inhibitors often leverages structural biology insights, allowing researchers to create compounds that can effectively disrupt the interaction between CRAMP1L and its molecular partners.
In research contexts, CRAMP1L inhibitors are utilized to dissect the functional roles of this protein within cellular systems. By employing these inhibitors, scientists can elucidate the mechanisms by which CRAMP1L contributes to various biological phenomena, including immune cell activation and modulation of inflammatory responses. These studies are essential for understanding the broader implications of CRAMP1L in cellular homeostasis and its potential involvement in various physiological processes. Additionally, CRAMP1L inhibitors serve as valuable tools in biochemical assays and experimental setups aimed at characterizing protein interactions, signaling pathways, and cellular responses under varying conditions. Overall, this chemical class is integral to advancing our comprehension of protein functions and interactions within biological systems.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
---|---|---|---|---|---|---|
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $150.00 $388.00 | 113 | |
A potent kinase inhibitor that can suppress the activity of multiple protein kinases, possibly affecting CRAMP1L if it is regulated by phosphorylation. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
An inhibitor of MEK, which is part of the MAPK/ERK pathway; could alter signaling events that involve CRAMP1L. | ||||||
MG-132 [Z-Leu- Leu-Leu-CHO] | 133407-82-6 | sc-201270 sc-201270A sc-201270B | 5 mg 25 mg 100 mg | $56.00 $260.00 $980.00 | 163 | |
A proteasome inhibitor that can prevent the degradation of proteins, potentially increasing the levels of CRAMP1L if it is normally degraded by the proteasome. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
A PI3K inhibitor that can affect AKT signaling and subsequently influence proteins associated with this pathway, including CRAMP1L. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
An mTOR inhibitor that can disrupt the mTOR signaling pathway, affecting protein synthesis and potentially the expression of CRAMP1L. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
A p38 MAPK inhibitor that can interfere with inflammatory responses and other p38-related signaling that may involve CRAMP1L. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
A PI3K inhibitor, similar to LY294002, that can prevent the phosphorylation and activation of downstream proteins, potentially affecting CRAMP1L. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
An inhibitor of JNK, part of the MAPK signaling pathway; could modulate CRAMP1L activity if it is impacted by stress-activated pathways. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $132.00 $1064.00 | 115 | |
A proteasome inhibitor, like MG132, which can stabilize proteins targeted for degradation, possibly influencing the levels of CRAMP1L. | ||||||
Z-VAD-FMK | 187389-52-2 | sc-3067 | 500 µg | $74.00 | 256 | |
A pan-caspase inhibitor that can block apoptosis, potentially affecting the degradation or cleavage of CRAMP1L during programmed cell death. |